Anlong Bio and Beijing Tiantan Hospital Forge Strategic Partnership to Advance Diagnosis and Treatment of Rare Neurological Diseases

Recently, at the annual meeting of the Neurology Center of Beijing Tiantan Hospital, Capital Medical University, Anlong and President Wang Yongjun and Vice President Wang Yilong of Tiantan Hospital officially signed a strategic cooperation agreement. The two parties will integrate their advantageous resources to carry out in-depth cooperation in the fields of diagnosis and treatment capacity building for rare neurological diseases, innovative drug research and development, and academic exchanges, jointly promoting the level of diagnosis and treatment of rare diseases in China to a new stage.

As the National Center for Neurological Diseases, Beijing Tiantan Hospital has long maintained a leading position in China in the diagnosis, treatment, and research of neurological diseases; while Anlong Biotechnology, as an innovative leader in gene therapy and RNA interference technology, has significant advantages in the development of cutting-edge therapies such as small interfering RNA (siRNA). This powerful collaboration will fully leverage the extensive clinical resources of Tiantan Hospital and Anlong's advanced biotechnology strengths, accelerating the research and clinical translation of innovative therapies, and bringing new hope to patients with rare neurological diseases.

Rare neurological diseases are diverse, including Spinal Muscular Atrophy (SMA), Huntington's disease, Multiple Sclerosis, etc. Although the number of patients with a single disease type is relatively small, the overall population faces challenges such as difficult diagnosis, limited treatment options, and low drug accessibility. The collaboration between Anlong Biotechnology and Tiantan Hospital aims to打通 “basic research - clinical translation - drug development - patient benefits” across the entire chain, providing more efficient solutions for patients with rare neurological diseases in China.

As a "benchmark" for the diagnosis and treatment of neurological diseases in China, Tiantan Hospital will leverage its rich clinical experience and case resources to assist Anlong in accurately identifying disease needs. Both parties will jointly conduct doctor training and multidisciplinary consultations (MDT) to improve the early diagnosis rate of rare diseases. Anlong, with its cutting-edge platforms such as gene therapy and RNA technology, will accelerate the development of original drugs targeting rare neurological diseases. Tiantan Hospital will provide clinical data and trial support to promote the rapid translation of drugs from the laboratory to clinical practice. Regularly share opportunities for international academic forums on rare neurological diseases, promoting exchanges between experts at home and abroad; jointly promote the construction of provincial and prefectural-level clinical and translational centers for rare neurological diseases.

Every step of progress in the treatment of rare disease patients embodies the power of medicine and technology. The collaboration between Anlong Bio and Beijing Tiantan Hospital is not only an integration of resources but also a vivid interpretation of the "patient-centered" concept. In the future, both parties will continue to deepen their cooperation, promoting China's diagnosis and treatment level of rare neurological diseases to achieve a historic leap from catching up, running alongside, to leading the way, contributing Chinese wisdom and solutions to the global prevention and treatment of rare diseases.

Beijing Tiantan Hospital, Capital Medical University, established in 1956, is a comprehensive tertiary hospital that leads in the development of clinical neuroscience and promotes the overall advancement of various disciplines. It serves as the National Clinical Research Center for Neurological Diseases, the National Quality Control Center for Neurological Diseases, and the National Medical Center for Neurological Diseases. Currently, the hospital has reached an internationally leading level in fields such as cerebrovascular diseases, intracranial tumors, and basic research on neuroinfectious and immune-related conditions. The quality of its clinical research is among the best in China, with some research projects reaching international advanced standards.